Cortechs.ai awarded million dollar NIH grant

The National Institute of Health awards Cortechs.ai a multi-million grant to quantify microstructural changes in Alzheimer’s Disease using Restriction Spectrum Imaging

SAN DIEGO (Aug. 10, 2022) – Cortechs.ai has received a $1.35 million, 2.5-year grant from the National Institutes of Health (NIH), National Institute on Aging to advance Alzheimer’s Disease (AD) diagnosis. The grant will allow Cortechs.ai to deliver an automated AI solution in a clinical setting to enable physicians to quickly determine a patient’s risk of developing AD, monitor disease progression and response to treatment. 

“We are thrilled to receive support from the NIA to further advance this promising technology in the area of Alzheimer’s Disease diagnosis,” said Nathan White, CTO of Cortechs.ai and co-inventor of Restriction Spectrum Imaging. “The development of new therapeutics for prevention and treatment of the disease would greatly benefit from robust, objective quantitative imaging biomarkers that reflect subtle underlying pathological brain changes that occur early in the disease process.”

Alzheimer’s Disease, a progressive neurodegenerative disorder, is characterized by β-amyloid deposits and neurofibrillary tangles preceding neuronal loss and cognitive decline. While diffusion imaging has been used effectively in diseases involving specific white matter pathways, the recent advances in diffusion imaging techniques – particularly multi-compartmental models for successfully quantifying microstructural changes – now enable the effective use of diffusion imaging in Alzheimer’s Disease. The project aims to use an advanced diffusion MRI technique called Restriction Spectrum Imaging to quantify the subtle microstructural changes in Alzheimer’s patients’ brains, making it possible to detect pathological changes in the brain without an autopsy.

Cortechs Labs holds the patent on “Restriction Spectrum Imaging.” The project titled “Quantifying microstructural changes in Alzheimer’s Disease using Restriction Spectrum Imaging” is one of many projects for which Cortechs.ai received research grants.

About Cortechs.ai

Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai’s cutting-edge brain imaging analysis provides neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, and brain development abnormalities. Please visit cortechs.ai for further information.

About NIH, National Institute on Aging

NIA, one of the 27 Institutes and Centers of NIH, leads the federal government in conducting and supporting research on aging and the health and well-being of older people. The Institute seeks to understand the nature of aging, the aging process, and diseases and conditions associated with growing older to extend the healthy, active years of life. Please visit nia.nih.gov for further information.

Media Contacts

Cortechs.ai

Dani Kuta

Marketing Manager

dkuta@cortechs.ai

+1 858 459-9700

 

NIH, National Institute on Aging

NIAPressTeam@mail.nih.gov

+1 301 496-1752

Insights

02/15/2025

NeuroQuant® Dementia: Advancing Alzheimer’s Disease Care in the Era of DMTs

AI-driven brain volumetric analysis is revolutionizing Alzheimer’s care, providing precise diagnostic support, monitoring, and early detection.

02/09/2025

NeuroQuant® MS:  Advancing Precision in Multiple Sclerosis

Dr. Suzie Bash discusses NeuroQuant MS, noting its ability to segment plaques, analyze volume, and track lesion burden for assessing disease progression

02/09/2025

Epilepsy Care with NeuroQuant Seizure: The Power of Quantifying Hippocampal Asymmetry

Accurate imaging of the hippocampus is crucial for effective diagnosis and treatment planning in TLE, with structural abnormalities linked to seizure onset
Scroll to Top